Matches 51 - 100 out of 448 < 1 2 3 4 5 6 7 8 9 >
Match Document Document Title
6642274 Methods and compositions for preventing and treating prostate disorders  
The present invention relates to methods, compositions, devices and kits for the prevention and treatment of prostate disorders in mammals, including, but not limited to, benign prostatic...
6632419 Increasing libido in humans via acute testosterone administration  
The libido of adult human female patients is increased by the bolus delivery of a testosterone which is preferably dihydrotestosterone. The formulation is preferably aerosolized and inhaled into a...
6610719 Use of prostaglandin (PGE2) receptor a (EP4) selective agonists for the treatment of acute and chronic renal failure  
This invention is directed to methods and compositions of treating acute or chronic renal failure or dysfunction, or conditions caused thereby, comprising administering prostaglandin agonists,...
6602487 Methods and tests for producing and for inhibiting coronary artery vasospasms  
Methods for producing coronary vasospasms and for inhibiting coronary vasospasms are disclosed. Both in vivo and in vitro methods are disclosed. The methods are useful as tests for determining the...
6596765 Treatment of ocular hypertension and glaucoma  
15-keto latanoprost and other 15-keto prostaglandin analogs are used as ocularly applied intraocular pressure reducing agents.
6593369 Methods, compositions, and kits for enhancing female sexual desire and responsiveness  
Topical application of a prostaglandin directly to the clitoris is effective for enhancing female sexual desire and responsiveness.
6589990 Methods and compositions for misoprostol compound treatment of erectile dysfunction  
Therapeutic formulations and methods for treating erectile dysfunction with a misoprostol compound in a subject are provided, a method comprising: obtaining a therapeutic formulation having an...
6589970 6-(aryl-amido or aryl-amidomethyl)-naphthalen-2-yloxy-acidic derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1)  
This invention provides novel compounds, pharmaceutical compositions and methods of treating thrombotic disorders in mammals, the compounds having the formula: Wherein: Ar is phenyl, naphthyl,...
6586457 Methods for inhibiting bone resorption  
The present invention relates to methods for inhibiting bone resorption in a mammal comprising administering to a mammal in need thereof a therapeutically effective amount of an EP 4 receptor...
6569900 Fulvic acid and its use in the treatment of various conditions  
Fulvic acid salts, esters or derivatives thereof in pharmaceutical preparations are effective for treating inflammation, acne, exzema or bacterial or fungal or viral infections. These...
6562782 Oligocycloalkanoid compounds and methods of use  
The present invention related to an oligocycloalkanoid compound comprising formula (I) wherein m, n, and o are independently an integer from 0 to 2; A 1 through A 10 are independently a direct...
6562868 Method for treatment of female sexual dysfunction  
A selective EP 2 or EP 4 prostanoid receptor agonist can be used to treat female sexual dysfunction. Salts and esters of the agonists can also be used. Formulations comprising such agonists,...
6559184 Methods and compositions for treating male erectile dysfunction  
Administration of a pharmaceutical composition in the form of a suppository comprising: (a) a prostaglandin vasodilator; (b) 15-hydroxyprostaglandindehydrogenase inhibitor: and (c) a base material...
6545045 Prostaglandin E agonists for treatment of glaucoma  
This application relates to compositions and methods for the treatment of glaucoma and/or ocular hypertension in mammals utilizing prostaglandin E receptor agonists.
6531139 Self-emulsifying formulation for lipophilic compounds  
The present invention provides a novel pharmaceutical composition based on the use of a particular oil phase which comprises a lipophilic, pharmaceutically active agent, a mixture of diglyceride...
6521212 Method for treating peripheral vascular disease by administering benzindene prostaglandins by inhalation  
A method of delivering benzindene prostaglandins to a patient by inhalation is discussed. A benzindene prostaglandin known as UT-15 has unexpectedly superior results when administered by inhalation...
6518305 Five-membered carbocyclic and heterocyclic inhibitors of neuraminidases  
Disclosed are compounds of the formula: which are useful for inhibiting neuraminidases from disease-causing microorganisms, especially, influenza neuraminidase. Also disclosed are compositions...
6503929 Nitrate salt of anti-ulcer medicine  
Nitrate salt compositions with anti-ulcer medicines having formula (A) and (B) wherein the (A) class compounds: R=H, OCH 3 , OCHF 2 ; R 1 =CH 3 , OCH 3 ; R 2 =H, CH 3 ; R 3 =CH 3 , CH 2 —CF 3 ,...
6495563 Method and composition for prevention of scar formation in glaucoma filtration bleb and drainage fistula  
This invention is related to a method whereby scar formation in the drainage fistula and subconjunctival bleb created during and after glaucoma surgery using a prostaglandin subtype A or J.
6492417 11-deoxy-16-fluoro-PGF2α analogs as FP receptor antagonists  
Methods and compositions for the antagonism of FP receptor-mediated biological responses are disclosed.
6476074 Method and composition for treatment of erectile dysfunction  
Compositions and methods for treatment of impotence or erectile dysfunction employ prostaglandins that are selective EP 2 or EP 4 prostanoid receptor agonists. The compositions can be formulated...
6472434 Method for minimizing excess collagen deposition  
Methods and formulations for minimizing excess collagen are provided. A pharmaceutical composition formulated so as to contain a selected vasoactive agent is administered to the vagina, vulvar area...
6469061 Jasmonate pharmaceutical composition for treatment of cancer  
A pharmaceutical composition useful for the treatment of cancer in mamnmals, comprising as the active ingredient a therapeutically effective amount of a jasmonate of the formula: wherein: n is...
6462082 Use of hydroxyeicosatetraenoic acid derivatives in intraocular surgery  
The use of HETE derivatives in intraocular surgery (e.g., cataract surgery) is disclosed. The HETE derivatives protect and maintain the corneal endothelium.
6462080 Prostaglandin E receptor agonists for treatment of dry eye  
The present invention relates to use of prostaglandin E receptor agonists and partial agonists to stimulate mucin secretion to treat dry eye, keratoconjunctivitis, Sjogren's syndrome and related...
6455584 Prostaglandin E1 derivatives  
To provide a prostaglandin derivative represented by the formula: wherein A is an ethylene group, a vinylene group, an ethynylene group, O(CH 2 ) q or S(O) r (CH 2 ) q , R 1 is a C 3-10 ...
6429226 Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension  
The invention relates to ophthalmological compositions for topical treatment of glaucoma or ocular hypertension comprising an effective intraocular pressure reducing amount of a prostaglandin...
6429227 Hydroxyeicosatetraenoate salts, compositions and methods of use in treating dry eye disorders  
HETE salts, the preparation of HETE salts, the preparation of stable and efficacious HETE compositions, HETE compositions and methods of use for treating dry eye are disclosed.
6420422 Ocular hypotensive agents  
The present invention relates to an ocular hypotensive composition and a composition for treatment of glaucoma which comprising an amount of 20-substituted-PGs or 20-substituted 15-keto-PGs...
6417228 13-Aza prostaglandins for the treatment of glaucoma and ocular hypertension  
13-Aza analogs of PGF 2α and methods of their use in treating glaucoma and ocular hypertension are disclosed.
6414022 Cyclopentane(ENE)heptenoic or heptenoic acids and derivatives thereof useful as therapeutic agents  
The invention relates to 7-[5-hydroxy-2-(hydroxyhydrocarbyl or heteroatom-substituted hydroxy hydrocarbyl)-3-hydroxy-cyclopentyl(enyl)] heptanoic or heptenoic acids and derivatives of said acids,...
6414028 Topical compositions containing prostaglandin E1  
A topical composition of a semi-solid consistency suitable is provided for transdermal application of prostaglandin E 1 . The composition comprises prostaglandin E 1 , a penetration enhancer, a...
6414021 Control of intraocular pressure during surgery  
An ocular infusion solution containing a prostaglandin-like compound or prostaglandin-analog is used during ocular surgery for maintaining desired intraocular pressure of the patient.
6410591 3,7 or 3 and 7 thia or oxa prostanoic acid derivatives as agents for lowering intraocular pressure  
The present invention provides a method of treating ocular hypertension or glaucoma which comprises administering to an animal having ocular hypertension or glaucoma a therapeutically effective...
6395744 Method and compositions for the treatment or amelioration of female sexual dysfunction  
The present invention provide a method of treating sexual dysfunction in a female, including the vasculogenic symptoms of delayed vaginal engorgement, diminished vaginal lubrication, pain or...
6395786 Sleep inducing agent  
A sleep-inducing preparation which comprises as an effective ingredient a prostaglandin derivative represented by the formula: wherein X is a halogen atom, Y is a group represented by (CH 2 ) m...
6376541 Upregulation of endogenous prostaglandins to lower intraocular pressure  
A method of lowering intraocular pressure (IOP) employs an upregulating agent that induces increased prostaglandin synthesis in the eye. The method of treatment entails administering to the eye of...
6372422 Multiple sexed embryo production system for mammals  
Improved insemination systems particularly adapted to use for sex-selected sperm sorting include systems which achieve superovulation and then multiple embryo production with sexed embryos. These...
6359001 Use of α-methyl-p-tyrosine to inhibit melanin production in iris melanocytes  
The use of agents for blocking the synthesis of tyrosinase to prevent permanent pigmentation of the iris caused by melanin deposit induced by pharmacological treatments or by metabolic imbalance is...
6353022 Compositions containing hydroxyeicosatetraenoic acid derivatives and methods of use in treating dry eye disorders  
Compositions containing one or more HETE derivative(s) and an effective concentration of ethanol and methods of use for treating dry eye are disclosed.
6344477 Prostaglandin e agonists for treatment of dry eye  
Compositions and methods for the treatment of dry eye and related diseases utilizing EP 4 receptor agonists are disclosed.
6344478 Use of cloprostenol and fluprostenol analogues to treat glaucoma and ocular hypertension  
Disclosed is the use of cloprostenol and fluprostenol analogues in combination with carbonic anhydrase inhibitors for the treatment of glaucoma and ocular hypertension and ophthalmic compositions...
6333354 Synergistic combination of PDE inhibitors and adenylate cyclase agonists or guanyl cyclyse agonists  
A diseased state based on acute or chronic obstruction of vessels and/or bronchi, acute or chronic inflammation and/or edema formation is advantageously treated by the combined administration of a...
6306841 Treatment of female sexual dysfunction  
Methods and formulations for treating female sexual dysfunction are provided. A pharmaceutical composition formulated so as to contain a selected vasoactive agent is administered to the vagina,...
6303588 Therapeutic methods utilizing naturally derived bio-active complexes and delivery systems therefor  
Methods are disclosed for correcting biological information transfer in a patient in need of such therapy which comprise administration to a patient of a composition comprising a therapeutically...
6294563 Combinations of prostaglandins and brimonidine or derivatives thereof  
The invention concerns combinations of alpha adrenergic agents such as brimonidine and its derivatives as represented by formula (I) below ##STR1## wherein each Y is independently selected from the...
6291521 Anti-portal hypertensive agent  
The present invention provides an anti-portal hypertensive agent comprising a 15-keto-prostaglandin compound as an active ingredient.
6291528 Prostaglandin E1/F2 in combination with prostaglandin F2α for enhancing female sexual arousal  
A method of treating and a composition for treating female sexual arousal dysfunction, comprising administering to the patient a unit dose of a formulation comprising an effective amount of a...
6288119 11,15-O-dialkylprostaglandin E derivatives, process for producing the same, and drugs containing the same as the active ingredient  
The present invention provides 11,15-O-dialkyl prostaglandin E derivatives of formula (I) ##STR1## (wherein all symbols are as described in Specification), or non-toxic salts thereof or...
6284773 Therapeutic combinations comprising a selective estrogen receptor modulator and prostaglandin E2  
This invention is directed to pharmaceutical combination compositions and methods comprising (-)-cis-6-phenyl-5-(4-(2-pyrrolidin-1-yl-ethoxy)-phenyl)-5,6 ,7,8-tetrahydr onaphthalene-2-ol or a...
Matches 51 - 100 out of 448 < 1 2 3 4 5 6 7 8 9 >